Guido Marcucci

Professor and the Francis & Kathleen McNamara Distinguished Chair of the Department of Hematology & Hematopoietic Cell Transplantation · City of Hope National Medical Center

Credentials: · · · ·

History

Department of Hematology & Hematopoietic Cell Transplantation · City of Hope National Medical Center
Present
Department of Hematology · City of Hope National Medical Center
Present
Division of Leukemia · City of Hope National Medical Center
Present

Roswell Park Comprehensive Cancer Center
1995–1997
University at Buffalo School of Medicine
1990–1993
Catholic University of the Sacred Heart
1986–1989
Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia 'Agostino Gemelli'
1982–1986

Research

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
New England Journal of Medicine · 2017 · 1,902 citations
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B
Proceedings of the National Academy of Sciences of the United States of America · 2007 · 1,320 citations
Targeting microRNAs in cancer: rationale, strategies and challenges
Review · Nature Reviews Drug Discovery · 2010 · 1,247 citations

CB
Clara Bloomfield
132 papers
MC
Michael Caligiuri
117 papers
Stephen Forman
109 papers
AS
Anthony Stein
108 papers
VP
Vinod Pullarkat
106 papers
Ibrahim Aldoss
102 papers
JB
John Byrd
84 papers
Ryotaro Nakamura
81 papers
AS
Amandeep Salhotra
77 papers
Haris Ali
75 papers
Richard Larson
71 papers
William Blum
67 papers

Grants

State-Transition and Leukemia Potential Dynamics to Inform Disease Evolution and Adaptive Therapy
National Cancer Institute · U01
PI · $1.8M · Beckman Research Institute/City of Hope
2024–2029
Targeting Immune Escape in CML/MPN Transformation
National Cancer Institute · R01
PI · $1.7M · Beckman Research Institute/City of Hope
2023–2028
Targeting MicroRNAs to Eradicate Leukemia Stem Cells
National Cancer Institute · R01
PI · $4.8M · Beckman Research Institute/City of Hope
2017–2027
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML
National Cancer Institute · R01
Contact PI · $2.7M · Beckman Research Institute/City of Hope
2022–2026

Clinical trials

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
Principal investigator · Withdrawn · Phase 1
City of Hope Medical Center
2022–2023
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
Principal investigator · Completed · Phase 1
City of Hope Medical Center
2017–2026
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Principal investigator · Terminated
Skyline Diagnostics BV
2011–2013
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2010–2021